April 15, 2025 - 18:44
PASADENA, Calif., April 15, 2025—Arrowhead Pharmaceuticals has announced the appointment of Daniel Apel as the new Chief Financial Officer, effective May 13, 2025. This transition comes as current CFO Ken Myszkowski prepares to retire after an impressive 16-year tenure with the company. Myszkowski has played a significant role in shaping the financial landscape of Arrowhead, and his contributions will be missed.
To ensure a smooth transition, Myszkowski will remain with the company in an advisory capacity, supporting Apel as he steps into his new role. Apel brings a wealth of experience and expertise to Arrowhead, having held various financial leadership positions in the biotechnology sector. His appointment is expected to bolster the company’s financial strategy as it continues to innovate in the pharmaceutical industry.
The leadership change marks a new chapter for Arrowhead, as it aims to enhance its operational efficiency and drive sustainable growth in the coming years.
